Document is current
Any future updates will be listed below
-
Authors
Helvacı, Özant https://orcid.org/0000-0002-1382-2439
Karaoğlan, Ayşegül https://orcid.org/0009-0004-7358-6599
Helvacı, Burçak Cavnar https://orcid.org/0000-0002-8356-4463
Güz, Galip https://orcid.org/0000-0002-9146-2133
Paşaoğlu, Hatice https://orcid.org/0000-0001-8343-7432
- License Information
-
More Information
Article History
Received: 27 December 2024
Accepted: 15 June 2025
First Online: 1 July 2025
Declarations
:
: Özant Helvacı has received honoraria from Boehringer Ingelheim (empagliflozin) and AstraZeneca (dapagliflozin) for delivering educational lectures to healthcare professionals unrelated to the current study. Other authors reveal no conflict of interest.
: This study was conducted in accordance with the 1964 Declaration of Helsinki. Ethical approval was obtained from the local Ethics Committee of Gazi University (E-77082166-604.01-921758). Informed consent was obtained from all participants prior to their inclusion in the study. Participants were assured of the confidentiality of their data and their right to withdraw from the study at any time without any consequences.
